Milnacipran Rivopharm (Milnacipran Hydrochloride)

Milnacipran, the active ingredient in Milnacipran Rivopharm, is a serotonin‑norepinephrine reuptake inhibitor presented as an oral dosage form for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Milnacipran Rivopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Milnacipran is an SNRI antidepressant that acts on the serotonin and norepinephrine pathways to improve mood and functional outcomes. - Major depressive disorder: reduces depressive symptoms and improves daily functioning. - Depression: alleviates low mood, loss of interest and associated cognitive deficits. - Major depressive episode: supports remission and prevents relapse when used as part of a comprehensive treatment plan.

Milnacipran may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Headache - Constipation - Dry mouth - Insomnia - Dizziness

Serious or Rare Side Effects: - Hypertension or marked increase in blood pressure - Tachycardia - Serotonin syndrome (potentially life‑threatening) - Suicidal thoughts or behavior, especially early in treatment - Severe liver injury or hepatitis

Milnacipran requires careful monitoring and specific safety considerations before and during therapy. - Assess cardiovascular status: monitor blood pressure and heart rate regularly. - Screen for suicidal ideation: evaluate risk before initiation and during early treatment. - Avoid abrupt discontinuation: taper the dose under medical supervision to reduce withdrawal symptoms. - Use caution in hepatic impairment: consider dose adjustment or enhanced monitoring. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Milnacipran can interact with several drug classes, necessitating vigilance to avoid adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertensive crisis and serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, tricyclic antidepressants, triptans, linezolid, tramadol): increased risk of serotonin syndrome. - Strong CYP2D6 inhibitors (e.g., quinidine, paroxetine): may raise milnacipran plasma levels.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol, tamoxifen): may require dose adjustment. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened risk of gastrointestinal bleeding. - Alcohol: may enhance central nervous system depression and dizziness.